AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29072677 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation with Pressure Controlled and Supported Breath (SIMV (PC) PS)
Number of subjects: 24
Study 27578117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly for 26 weeks
Number of subjects: 7
Study 27578117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 27578117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen in open-label extension (OLE) for 52 or 104 weeks
Number of subjects: 7
Study 25394366 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel dual-site differential control
Number of subjects: 5
Study 25394366 — intervention group
Group type: COMPARATOR
Intervention: Sequential pattern recognition control
Number of subjects: 5
Study 23546562 — intervention group
Group type: EXPERIMENTAL
Intervention: Group incentive ($500 per month split among participants within groups of 5 who met or exceeded weight-loss goals)
Number of subjects: 105
Study 23546562 — intervention group
Group type: EXPERIMENTAL
Intervention: Group incentive
Number of subjects: 105
Study 23546562 — intervention group
Group type: COMPARATOR
Intervention: Control (24 weeks of monthly weigh-ins)
Number of subjects: 105
Study 23546562 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual incentive ($100 per person per month for meeting or exceeding weight-loss goals)
Number of subjects: 105
Study 20951487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet plus low-dose activated vitamin D analogues (Cinacalcet-D)
Number of subjects: 0
Study 20951487 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D analogues alone (Flex-D)
Number of subjects: 0
Study 20951487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet plus vitamin D analogues (Cinacalcet-D)
Number of subjects: 0
Study 20951487 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to generic calcitriol
Number of subjects: 0
Study 20951487 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching sevelamer to lanthanum
Number of subjects: 0
Study 18562104 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg)
Number of subjects: 55
Study 18562104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16860459 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional video-laparoscopy pelvic trainer
Number of subjects: 36
Study 16860459 — intervention group
Group type: COMPARATOR
Intervention: Cardboard box with a cut-out top
Number of subjects: 36
Study 12000492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic 'real world' randomized trials
Number of subjects: 0
Study 9658990 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 54
Study 9658990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 7543713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units 2 hours before operation and 5000 units every 8 hours for 5 days after operation)
Number of subjects: 89
Study 7543713 — intervention group
Group type: COMPARATOR
Intervention: Dextran 40 (administered during the operation with an additional infusion of 500 ml/day for the next 3 days)
Number of subjects: 89
Study 2795401 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent present during injection
Number of subjects: 47
Study 2795401 — intervention group
Group type: COMPARATOR
Intervention: Parent absent during injection
Number of subjects: 47
Study 338206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 47
Study 338206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: STI‐12 starter culture
Number of subjects: 5
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: RST‐743 starter culture
Number of subjects: 5
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐707 starter culture
Number of subjects: 5
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: XPL‐2 starter culture
Number of subjects: 5
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: CHN‐22 starter culture
Number of subjects: 5
Study 30591338 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer preferences
Number of subjects: 5
Study 30549494 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD)
Number of subjects: 311
Study 30549494 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 311
Study 26769482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmojet
Number of subjects: 421
Study 26769482 — intervention group
Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 421
Study 26769482 — intervention group
Group type: COMPARATOR
Intervention: Turbohaler
Number of subjects: 421
Study 24740662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage tamoxifen (80 mg/day) administered from six weeks prior until twelve weeks after surgery
Number of subjects: 30
Study 24740662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22147649 — intervention group
Group type: EXPERIMENTAL
Intervention: MDX-1100 (10 mg/kg every other week)
Number of subjects: 70
Study 22147649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19079815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 205
Study 19079815 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (Lam)
Number of subjects: 205
Study 17979011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy programme (3-day programme with 7 specific exercises, lasting approximately one hour)
Number of subjects: 58
Study 17979011 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mainly consisting of walking)
Number of subjects: 58
Study 16334120 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 1‐h or 3‐h infusions of paclitaxel
Number of subjects: 21
Study 16334120 — intervention group
Group type: EXPERIMENTAL
Intervention: T(>0.05) > or = 20.7 hours
Number of subjects: 21
Study 11986448 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension, 0.5 mg daily (n = 168)
Number of subjects: 335
Study 11986448 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium nebulizer solution, 20 mg 4 times daily (n = 167)
Number of subjects: 335
Study 11986448 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Number of subjects: 335
Study 9535299 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 23
Study 9535299 — intervention group
Group type: COMPARATOR
Intervention: Minimal therapy (control)
Number of subjects: 23
Study 7893023 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine 70 micrograms/kg + glycopyrrolate 10 micrograms/kg, i.v.
Number of subjects: 113
Study 7893023 — intervention group
Group type: EXPERIMENTAL
Intervention: edrophonium 1 mg/kg + atropine 10 micrograms/kg, i.v.
Number of subjects: 113
Study 7893023 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 113
Study 2798577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 30
Study 2798577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 328210 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg propantheline
Number of subjects: 13
Study 328210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31072180 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus methylprednisolone
Number of subjects: 74
Study 31072180 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 74
Study 27576860 — intervention group
Group type: EXPERIMENTAL
Intervention: CLT-28643 (single subconjunctival injection intraoperatively) followed by postoperative vehicle eye drops (CLT+ group)
Number of subjects: 24
Study 27576860 — intervention group
Group type: EXPERIMENTAL
Intervention: CLT-28643 (single subconjunctival injection intraoperatively) followed by CLT-28643 eye drops 4 times daily (CLT++ group)
Number of subjects: 24
Study 27576860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) (0.04%, sponge application, 2 min) followed by vehicle eye drops postoperatively (MMC group)
Number of subjects: 24
Study 27576860 — intervention group
Group type: COMPARATOR
Intervention: Control-surgery group (no adjunctive therapy)
Number of subjects: 24
Study 26293513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 60
Study 26293513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 60
Study 26293513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26293513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50 and 75 mg)
Number of subjects: 60
Study 23320451 — intervention group
Group type: EXPERIMENTAL
Intervention: Octaplas LG plasma product
Number of subjects: 60
Study 23320451 — intervention group
Group type: COMPARATOR
Intervention: Octaplas S/D plasma product
Number of subjects: 60
Study 21928240 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus block (BPB) with 15 mL ropivacaine 1% and 10 mL saline via axillary approach
Number of subjects: 40
Study 21928240 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with lidocaine 2%
Number of subjects: 40
Study 19550413 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-precut group (n=77)
Number of subjects: 151
Study 19550413 — intervention group
Group type: COMPARATOR
Intervention: Late-access group (n=74)
Number of subjects: 151
Study 17463075 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS application for 60 minutes daily
Number of subjects: 32
Study 17463075 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS application for 8 hours daily
Number of subjects: 32
Study 15465747 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma selenium levels
Number of subjects: 949
Study 11885210 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 68)
Number of subjects: 93
Study 11885210 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 93
Study 9551703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on day 1 and 200 mg on days 2-4)
Number of subjects: 11
Study 9551703 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 11
Study 9551703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1760050 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular lager (4.2%)
Number of subjects: 0
Study 1760050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol lager
Number of subjects: 0
Study 1760050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol lager
Number of subjects: 0
Study 1760050 — intervention group
Group type: COMPARATOR
Intervention: Topping-up with non-alcohol lager
Number of subjects: 0
Study 1760050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topping-up with low-alcohol lager
Number of subjects: 0
Study 7059257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program focusing on pill taking, appointment keeping, and dietary sodium reduction
Number of subjects: 39
Study 7059257 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 39
Study 30789492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 636
Study 30789492 — intervention group
Group type: COMPARATOR
Intervention: Control (postoperative analgesics only)
Number of subjects: 636
Study 28583301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy including support of hospital leadership, use of order sets, audit and feedback, and active pharmacy involvement
Number of subjects: 8
Study 28583301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy
Number of subjects: 8
Study 28583301 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified intervention)
Number of subjects: 8
Study 26902700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris
Number of subjects: 60
Study 24509134 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatabine
Number of subjects: 17
Study 24509134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 24509134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 17
Study 22424002 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA as the first diagnostic test following serial biomarkers
Number of subjects: 1000
Study 22424002 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no testing or functional testing such as exercise ECG, stress radionuclide imaging, or stress echocardiography)
Number of subjects: 1000
Study 22424002 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1000
Study 22424002 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1000
Study 20378381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 207
Study 20378381 — intervention group
Group type: COMPARATOR
Intervention: Caliper (CLP) measurements
Number of subjects: 207
Study 20378381 — intervention group
Group type: COMPARATOR
Intervention: Circumference (CF) measurements
Number of subjects: 207
Study 18728907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 hours of weekly, mandatory physical exercise of middle-to-high intensity
Number of subjects: 177
Study 18728907 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of full-time weekly workhours from 40 to 37.5 hours
Number of subjects: 177
Study 18728907 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 177
Study 15903382 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n = 52) participated in 2 field-training sessions per week.
Number of subjects: 68
Study 15903382 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (n = 16).
Number of subjects: 68
Study 12566015 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%/dorzolamide 2% fixed combination
Number of subjects: 32
Study 12566015 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% and unoprostone 0.15%
Number of subjects: 32
Study 10234600 — intervention group
Group type: COMPARATOR
Intervention: Argatroban 1 microgram/kg/min infused alone for 5 hours (regimen A)
Number of subjects: 14
Study 10234600 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 1 microgram/kg/min infused on day 6 of a 7-day oral regimen of 500 mg erythromycin four times daily (regimen B)
Number of subjects: 14
Study 9193325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/d
Number of subjects: 148
Study 9193325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 148
Study 1534993 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/ml sufentanil in saline (Group S)
Number of subjects: 73
Study 1534993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/ml sufentanil in 0.125% bupivacaine (Group SB)
Number of subjects: 73
Study 1534993 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 73
Study 3456271 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m2 iv every 3 weeks)
Number of subjects: 42
Study 3456271 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2 iv every 3 weeks)
Number of subjects: 42
Study 3456271 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 42
Study 3456271 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 42
Study 31409671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 210
Study 30005094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% and Benzocaine 20%
Number of subjects: 14
Study 30005094 — intervention group
Group type: COMPARATOR
Intervention: Compounded Lidocaine 23%/Tetracaine 7% (23/7)
Number of subjects: 14
Study 27235515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 72
Study 27235515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24284272 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT)
Number of subjects: 99
Study 24284272 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 99
Study 24284272 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 99
Study 22401811 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with cumulus cells (Group A)
Number of subjects: 46
Study 22401811 — intervention group
Group type: COMPARATOR
Intervention: Vitrification without cumulus cells (Group B)
Number of subjects: 46
Study 20810892 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-response tasks with motor planning (desired goals)
Number of subjects: 0
Study 20810892 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-response tasks with motor planning (undesired goals)
Number of subjects: 0
Study 20810892 — intervention group
Group type: COMPARATOR
Intervention: Memory/attention-only conditions
Number of subjects: 0
Study 17630262 — intervention group
Group type: EXPERIMENTAL
Intervention: Group affirmation (affirming an important group value)
Number of subjects: 0
Study 15662234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose controlled-release nifedipine (20 mg/day) plus candesartan (8 mg/day) combination therapy
Number of subjects: 0
Study 15662234 — intervention group
Group type: COMPARATOR
Intervention: Up-titrated candesartan (12 mg/day) monotherapy
Number of subjects: 0
Study 12693152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular HBV vaccine (20 micrograms each dose) at 0, 1, and 6 month intervals
Number of subjects: 96
Study 12693152 — intervention group
Group type: COMPARATOR
Intervention: Intradermal HBV vaccine (2 micrograms each dose) at 0, 1, and 6 month intervals
Number of subjects: 96
Study 10090959 — intervention group
Group type: EXPERIMENTAL
Intervention: Invaginating stripping of the LSV
Number of subjects: 30
Study 10090959 — intervention group
Group type: COMPARATOR
Intervention: Classic stripping of the LSV
Number of subjects: 30
Study 8771155 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR assay for detecting rearranged Ig heavy chain genes
Number of subjects: 140
Study 8771155 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR assay
Number of subjects: 140
Study 8771155 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis of B-cell lymphoproliferative disease
Number of subjects: 140
Study 1835292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.036 mg)
Number of subjects: 72
Study 1835292 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (0.18 mg)
Number of subjects: 72
Study 1835292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7333755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position at rest
Number of subjects: 12
Study 7333755 — intervention group
Group type: COMPARATOR
Intervention: Supine position at rest
Number of subjects: 12
Study 7333755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during dynamic exercise
Number of subjects: 12
Study 7333755 — intervention group
Group type: COMPARATOR
Intervention: Supine position during dynamic exercise
Number of subjects: 12
Study 7333755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position and Supine position
Number of subjects: 12
Study 31377160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) alone
Number of subjects: 2995
Study 31377160 — intervention group
Group type: COMPARATOR
Intervention: Radiation Therapy (RT) alone
Number of subjects: 2995
Study 28647759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom Power parenting intervention
Number of subjects: 122
Study 28647759 — intervention group
Group type: COMPARATOR
Intervention: Weekly mailings of parenting information (control)
Number of subjects: 122
Study 25556985 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 26
Study 25556985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (exercise, diet, and hot bathing) - Group A
Number of subjects: 66
Study 23095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention - Group B
Number of subjects: 66
Study 23095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot bathing intervention - Group C
Number of subjects: 66
Study 23095006 — intervention group
Group type: COMPARATOR
Intervention: Control group - Group D
Number of subjects: 66
Study 21343393 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly (A:U) dsRNA
Number of subjects: 194
Study 20209742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B ESL educational curriculum
Number of subjects: 325
Study 20209742 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard ESL education without hepatitis B curriculum)
Number of subjects: 325
Study 18552044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day cetirizine
Number of subjects: 37
Study 18552044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day levocetirizine
Number of subjects: 37
Study 18552044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15472793 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued PI-based therapy
Number of subjects: 45
Study 15472793 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine usage
Number of subjects: 45
Study 15472793 — intervention group
Group type: COMPARATOR
Intervention: Control of viral replication
Number of subjects: 45
Study 15472793 — intervention group
Group type: COMPARATOR
Intervention: Lipid and glycemic parameters
Number of subjects: 45
Study 11486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 67
Study 11486240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 67
Study 11486240 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 67